Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Liminatus Pharma, Inc. Warrants (LIMNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: LIMNW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -92% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.05 - 0.47 | Updated Date 06/26/2025 |
52 Weeks Range 0.05 - 0.47 | Updated Date 06/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Liminatus Pharma, Inc. Warrants
Company Overview
History and Background
There is no publicly traded company called 'Liminatus Pharma, Inc. Warrants'. The analysis cannot be performed without a real company. This response is based on general warrant analysis, not specific to a non-existent company.
Core Business Areas
- Pharmaceutical Research and Development: Focuses on discovering, developing, and commercializing innovative pharmaceutical products.
Leadership and Structure
Information unavailable for a non-existent company.
Top Products and Market Share
Key Offerings
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high regulatory hurdles, and significant investment in research and development. The industry is experiencing growth due to aging populations and increasing healthcare expenditure.
Positioning
Cannot be determined for a non-existent company.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated at over $1 trillion. Without knowing the specific focus of Liminatus Pharma, Inc., determining its position within the TAM is impossible.
Upturn SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
Competitors and Market Share
Key Competitors
Competitive Landscape
Cannot be determined for a non-existent company.
Growth Trajectory and Initiatives
Historical Growth: No data available.
Future Projections: No data available.
Recent Initiatives: No data available.
Summary
Without information about Liminatus Pharma, Inc. Warrants, it's impossible to assess its strength or weakness. An analysis cannot be performed on a non-existent company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings (hypothetical)
- Industry reports (hypothetical)
Disclaimers:
The analysis is based on a hypothetical company and general warrant characteristics. The data and analysis are not indicative of any real company's performance. This analysis is for demonstration purposes only and should not be used for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Liminatus Pharma, Inc. Warrants
Exchange NASDAQ | Headquaters La Palma, CA, United States | ||
IPO Launch date 2025-05-01 | CEO, Treasurer & Secretary Mr. Chris Kim J.D., L.L.M. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://liminatuspharma.com |
Full time employees - | Website https://liminatuspharma.com | ||
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.